BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 15925990)

  • 1. Alterations of cell cycle regulators in gliomatosis cerebri.
    Mawrin C; Kirches E; Schneider-Stock R; Boltze C; Vorwerk CK; von Mawrin A; Kirches E; Schneider-Stock R; Boltze C; Vorwerk CK; von Mawrin A; Kirches E; Schneider-Stock R; Boltze C; Vorwerk CK; von Mawrin A; Kirches E; Schneider-Stock R; Boltze C; Vorwerk CK; von Deimling A; Stoltenburg-Didinge G; Bornemann A; Romeike B; Sellhaus B; Dietzmann K
    J Neurooncol; 2005 Apr; 72(2):115-22. PubMed ID: 15925990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of molecular genetic alterations associated with tumor progression in a case of gliomatosis cerebri.
    Braeuninger S; Schneider-Stock R; Kirches E; Powers JM; Korones DN; Mawrin C
    J Neurooncol; 2007 Mar; 82(1):23-7. PubMed ID: 16955219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gliomatosis cerebri: molecular pathology and clinical course.
    Herrlinger U; Felsberg J; Küker W; Bornemann A; Plasswilm L; Knobbe CB; Strik H; Wick W; Meyermann R; Dichgans J; Bamberg M; Reifenberger G; Weller M
    Ann Neurol; 2002 Oct; 52(4):390-9. PubMed ID: 12325066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic alterations commonly found in diffusely infiltrating cerebral gliomas are rare or absent in pleomorphic xanthoastrocytomas.
    Kaulich K; Blaschke B; Nümann A; von Deimling A; Wiestler OD; Weber RG; Reifenberger G
    J Neuropathol Exp Neurol; 2002 Dec; 61(12):1092-9. PubMed ID: 12484572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Could changes in the regulation of the PI3K/PKB/Akt signaling pathway and cell cycle be involved in astrocytic tumor pathogenesis and progression?
    Hlobilkova A; Ehrmann J; Sedlakova E; Krejci V; Knizetova P; Fiuraskova M; Kala M; Kalita O; Kolar Z
    Neoplasma; 2007; 54(4):334-41. PubMed ID: 17822324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of tumor cell invasion factors in gliomatosis cerebri.
    Mawrin C; Schneider T; Firsching R; Wiedemann FR; Dietzmann K; Bornemann A; Romeike BF; Sellhaus B; von Deimling A
    J Neurooncol; 2005 Jun; 73(2):109-15. PubMed ID: 15981099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aberrant expression of the cell cycle associated proteins TP53, MDM2, p21, p27, cdk4, cyclin D1, RB, and EGFR in cervical carcinomas.
    Skomedal H; Kristensen GB; Lie AK; Holm R
    Gynecol Oncol; 1999 May; 73(2):223-8. PubMed ID: 10329038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic profile of gliosarcomas.
    Reis RM; Könü-Lebleblicioglu D; Lopes JM; Kleihues P; Ohgaki H
    Am J Pathol; 2000 Feb; 156(2):425-32. PubMed ID: 10666371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of TP53 and PTEN in gliomatosis cerebri.
    Mawrin C; Kirches E; Schneider-Stock R; Scherlach C; Vorwerk C; Von Deimling A; Van Landeghem F; Meyermann R; Bornemann A; Müller A; Romeike B; Stoltenburg-Didinger G; Wickboldt J; Pilz P; Dietzmann K
    Acta Neuropathol; 2003 Jun; 105(6):529-36. PubMed ID: 12734658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic aberrations in gliomatosis cerebri support monoclonal tumorigenesis.
    Kros JM; Zheng P; Dinjens WN; Alers JC
    J Neuropathol Exp Neurol; 2002 Sep; 61(9):806-14. PubMed ID: 12230327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distribution of p53 alterations in a case of gliomatosis cerebri.
    Mawrin C; Lins H; Kirches E; Schildhaus HU; Scherlach C; Kanakis D; Dietzmann K
    Hum Pathol; 2003 Jan; 34(1):102-6. PubMed ID: 12605375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deregulation of the TP53/p14ARF tumor suppressor pathway in low-grade diffuse astrocytomas and its influence on clinical course.
    Watanabe T; Katayama Y; Yoshino A; Komine C; Yokoyama T
    Clin Cancer Res; 2003 Oct; 9(13):4884-90. PubMed ID: 14581362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathways leading to glioblastoma multiforme: a molecular analysis of genetic alterations in 65 astrocytic tumors.
    Lang FF; Miller DC; Koslow M; Newcomb EW
    J Neurosurg; 1994 Sep; 81(3):427-36. PubMed ID: 8057151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors.
    Ueki K; Nishikawa R; Nakazato Y; Hirose T; Hirato J; Funada N; Fujimaki T; Hojo S; Kubo O; Ide T; Usui M; Ochiai C; Ito S; Takahashi H; Mukasa A; Asai A; Kirino T
    Clin Cancer Res; 2002 Jan; 8(1):196-201. PubMed ID: 11801559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pilocytic astrocytomas do not show most of the genetic changes commonly seen in diffuse astrocytomas.
    Cheng Y; Pang JC; Ng HK; Ding M; Zhang SF; Zheng J; Liu DG; Poon WS
    Histopathology; 2000 Nov; 37(5):437-44. PubMed ID: 11119125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Roles of the functional loss of p53 and other genes in astrocytoma tumorigenesis and progression.
    Nozaki M; Tada M; Kobayashi H; Zhang CL; Sawamura Y; Abe H; Ishii N; Van Meir EG
    Neuro Oncol; 1999 Apr; 1(2):124-37. PubMed ID: 11550308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accumulation of MDM2 in pleomorphic xanthoastrocytomas.
    Matsumoto K; Suzuki SO; Fukui M; Iwaki T
    Pathol Int; 2004 Jun; 54(6):387-91. PubMed ID: 15144396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression Analysis of Genes Involved in the RB/E2F Pathway in Astrocytic Tumors.
    Ferreira WA; Araújo MD; Anselmo NP; de Oliveira EH; Brito JR; Burbano RR; Harada ML; Borges Bdo N
    PLoS One; 2015; 10(8):e0137259. PubMed ID: 26317630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic aberrations leading to MAPK pathway activation mediate oncogene-induced senescence in sporadic pilocytic astrocytomas.
    Jacob K; Quang-Khuong DA; Jones DT; Witt H; Lambert S; Albrecht S; Witt O; Vezina C; Shirinian M; Faury D; Garami M; Hauser P; Klekner A; Bognar L; Farmer JP; Montes JL; Atkinson J; Hawkins C; Korshunov A; Collins VP; Pfister SM; Tabori U; Jabado N
    Clin Cancer Res; 2011 Jul; 17(14):4650-60. PubMed ID: 21610151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutations of TP53, amplification of EGFR, MDM2 and CDK4, and deletions of CDKN2A in malignant astrocytomas.
    Biernat W; Debiec-Rychter M; Liberski PP
    Pol J Pathol; 1998; 49(4):267-71. PubMed ID: 10323080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.